Oncología

Resultados: 397
Tipo Título / Nombre Autor(es) Año
Coping strategies as mediators of uncertainty and psychological distress in patients with advanced cancer Obispo B, Cruz-Castellanos P, Fernández-Montes A, Coca-Membribes S, Rogado J..., López-Ceballos H, et al 2023
The Role of Financial Difficulties as a Mediator between Physical Symptoms and Depression in Advanced Cancer Patients Lee EM, Jiménez-Fonseca P, Hernández R, Cruz-Castellanos P, Fernández-Montes A..., López-Ceballos H, et al 2023
What do patients and oncologists think about the evaluation and management of cancer?related anorexia?cachexia? The Quasar_ SEOM study Escobar Y, Ramchandani A, Castillo-Trujillo A, Martínez de Castro E..., Borrega P 2023
ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis Ciruelos EM, Tolosa Ortega P, Salvador Bofill FJ, González Santiago S, Albacar Miro CR 2023
Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa González Santiago S, López Miranda E, Escrivá Romani S, Jiménez Rodríguez B, Antolin Novoa S, González Cortijo L, et al 2023
Infección fúngica en paciente oncológico Espacio Santos PM 2023
Síndromes paraneoplásicos en carcinoma de células renales ( a propósito de un caso) Espacio Santos PM 2023
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study Manzano JL, Martín-Liberal J, Fernández-Morales LA, Benítez G, Medina Martínez J..., Ayala de Miguel P, et al 2023
Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study Alés-Martínez JE, Balmaña J, Sánchez-Rovira P, Salvador Bofill FJ..., López Ceballos MH 2023
SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer (MBC) Ciruelos E, Perelló A, González Santiago S 2023